semaglutide gag reflex NoGag® Case GLP-1s May Lead to an

Cagrilintide vs tirzepatide (Mounjaro/Zepbound) Mechanism: Cagrilintide: Amylin agonist Tirzepatide: Dual GIP/GLP-1 agonist Both novel approaches Weight loss: Cagrilintide: 10-12% monotherapy Tirzepatide: 15-22% monotherapy Tirzepatide superior as single agent Administration: Both: Weekly subcutaneous injection Both: Similar convenience Side effects: Cagrilintide: Strong GI effects Tirzepatide: Moderate GI effects Similar overall profile Approval status: Cagrilintide: Investigational Tirzepatide: FDA approved Tirzepatide available now Cost (when both available): Likely similar ($1,000-1,500/month) Both premium weight loss options Verdict: Currently, tirzepatide better choice (approved, superior weight loss)

Some UHC Medicare Advantage plans have begun offering limited coverage, particularly under additional FDA-approved indications such as Wegovys cardiovascular indication (PEAK does not accept Medicare Advantage plans)

The majority of patients do not experience clinically significant tachycardia (defined as heart rate exceeding 100 beats per minute at rest)

So if you're still in your first month or two of taking the weight loss drug, it might be worth sticking it out

Front Pharmacol:11